ASU begins clinical study for cancer-preventing vaccineMay 10, 2019An Arizona State University (ASU) professor has begun a five-year clinical study examining the effectiveness of a cancer-preventing vaccine for dogs. Stephen Johnston, PhD, a scientist, professor at the School of Life Sciences, and director of the Biodesign Center for Innovations in Medicine, developed the vaccine over a span of 12 years. He says his goal is to change the way veterinarians treat cancer by preventing it before it can start. Over the course of the five-year study, 800 dogs will either be given the vaccine or a placebo and will be monitored. The University of Wisconsin (UW) School of Veterinary Medicine, Colorado State University (CSU) and University of California (UC), Davis are also participating in the trial. "We're testing a totally novel way of creating an anticancer immune response," says David Vail, DVM, DACVIM (oncology), professor and board-certified oncologist at the UW School of Veterinary Medicine. "The holy grail would be to prevent cancer as opposed to waiting for it to start and then treating it." The vaccine is designed to target common canine cancers, including lymphoma, osteosarcoma, hemangiosarcoma, and mastocytomas. At the beginning, two sets of vaccines will be given every two weeks and then annually. The …
SPONSORED CONTENTYour Parasite Protection Recommendation, SimplifiedManaging parasite prevention doesn’t have to be complicated. Discover a single solution that protects against multiple threats. + Learn More
Tell me about your puppyhood...February 2, 2018The Canine Science Collaboratory, located in the Department of Psychology at Arizona State University in Tempe, is on a unique mission: to better understand the behavior and cognition of dogs and their wild relatives. It’s an ambitious goal with tremendous implications for dogs, owners, veterinarians, and others who work with one of America’s most popular pets.
ASU awarded $6.4M grant to test preventive canine cancer vaccineJanuary 8, 2018Arizona State University (ASU) professor Stephen Albert Johnson, Ph.D., has received a $6.4 million grant from the Open Philanthropy Project to support a clinical trial of a vaccine to prevent canine cancer. The trial will involve approximately 800 middle-aged, healthy pet dogs and will test the effects of a multivalent frameshift peptide (FSP) vaccine developed at ASU that has shown promise in mouse studies. Scientists think the vaccine has potential for human use, too. "Our goal has always been that if this is possible, we should at least try it," said Johnston, director of the Biodesign Center for Innovations in Medicine and CEO of Calviri Inc., a cancer vaccine company. "Open Philanthropy was the only organization that responded to support our high-risk project, the biggest cancer intervention trial in dogs ever." Johnston and his team developed the new FSP vaccine over the past 10 years. The vaccine, already tested for efficacy in mice, is shown to be safe in dogs, according to Johnston's research. Cancer is the leading cause of death in pet dogs and their cancers are very similar to their human counterparts. Some breeds have a very high cancer rate, as much as 40 percent. The canine …
